Connect Biopharma Holdings Limited (CNTB)
| Previous close | 1.5200 |
| Open | 1.4600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.4496 - 1.5799 |
| 52-week range | 0.5350 - 2.8400 |
| Volume | |
| Avg. volume | 167,024 |
| Market cap | 81.569M |
| Beta (5Y monthly) | -0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0800 |
| Earnings date | 16 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireConnect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe atopic dermatitis (AD)Type C meeting in AD and End-of-Phase 2 (EoP2) meeting in asthma have been scheduled with the U.S. Food and Drug Administration (FDA) in Q2 2024 to discuss trial results and proposed registrational programsGranted Simcere the exclusive rights to develop, manufacture, and comme
- GlobeNewswire
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. W
- GlobeNewswire
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven resear
